AstraZeneca PLC (LON:AZN - Get Free Report) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of £133.11 and traded as high as £147.90. AstraZeneca shares last traded at £146.50, with a volume of 27,232,461 shares changing hands.
Wall Street Analyst Weigh In
AZN has been the topic of several research reports. Berenberg Bank lifted their target price on AstraZeneca from £145 to £160 and gave the stock a "buy" rating in a report on Tuesday, January 27th. Shore Capital Group reissued a "buy" rating on shares of AstraZeneca in a research note on Friday, January 16th. JPMorgan Chase & Co. restated an "overweight" rating on shares of AstraZeneca in a report on Thursday, January 15th. Citigroup started coverage on AstraZeneca in a research note on Tuesday, January 27th. They issued a "buy" rating and a £170 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on AstraZeneca from £105 to £110 and gave the stock a "sell" rating in a report on Thursday, January 15th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, AstraZeneca currently has an average rating of "Moderate Buy" and an average price target of £145.83.
Read Our Latest Analysis on AZN
AstraZeneca Stock Performance
The business's fifty day moving average price is £143.48 and its two-hundred day moving average price is £133.11. The company has a debt-to-equity ratio of 60.87, a quick ratio of 0.59 and a current ratio of 0.94. The stock has a market capitalization of £227.19 billion, a P/E ratio of 22.40, a P/E/G ratio of 0.86 and a beta of 0.23.
Insider Buying and Selling
In related news, insider Nazneen Rahman sold 297 shares of AstraZeneca stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of £134.96, for a total value of £40,083.12. Corporate insiders own 0.14% of the company's stock.
AstraZeneca Company Profile
(
Get Free Report)
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
